FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3033156668> ?p ?o ?g. }

• W3033156668 abstract "Abstract Importance There is a controversy regarding whether or not to continue angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in patients with coronavirus disease 2019 (COVID-19). Objective To evaluate the association between ACEIs or ARBs use and clinical outcomes in COVID-19 patients. Data Sources Systematic search of the PubMed, Embase, Scopus, Web of Science, and Cochrane Central Register of Controlled Trials from database inception to May 31, 2020. We also searched the preprint servers medRxiv and SSNR for additional studies. Study Selection Observational studies and randomized controlled trials reporting the effect of ACEIs or ARBs use on clinical outcomes of adult patients with COVID-19. Data Extraction and Synthesis Risk of bias of observational studies were evaluated using the Newcastle-Ottawa Scale. Meta-analyses were performed using a random-effects models and effects expressed as Odds ratios (OR) and mean differences with their 95% confidence interval (95%CI). If available, adjusted effects were pooled. Main Outcomes and Measures The primary outcome was all-cause mortality and secondary outcomes were COVID-19 severity, hospital discharge, hospitalization, intensive care unit admission, mechanical ventilation, length of hospital stay, and troponin, creatinine, procalcitonin, C-reactive protein (CRP), interleukin-6 (IL-6), and D-dimer levels. Results 40 studies (21 cross-sectional, two case-control, and 17 cohorts) involving 50615 patients were included. ACEIs or ARBs use was not associated with all-cause mortality overall (OR 1.11, 95%CI 0.77-1.60, p=0.56), in subgroups by study design and using adjusted effects. ACEI or ARB use was independently associated with lower COVID-19 severity (aOR 0.56, 95%CI 0.37-0.87, p<0.01). No significant associations were found between ACEIs or ARBs use and hospital discharge, hospitalization, mechanical ventilation, length of hospital stay, and biomarkers. Conclusions and Relevance ACEIs or ARBs use was not associated with higher all-cause mortality in COVID-19. However, ACEI or ARB use was independently associated with lower COVID-19 severity. Our results support the current international guidelines to continue the use of ACEIs and ARBs in COVID-19 patients with hypertension. Key points Question What is the association between angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) use and clinical outcomes in coronavirus disease 2019 (COVID-19) patients? Findings In this systematic review and meta-analysis of 40 observational studies, the use of ACEIs or ARBs was not associated with higher all-cause mortality in COVID-19 patients. Additionally, ACEIs or ARBs use was independently associated with lower COVID-19 severity. Meaning These results support the current international guidelines to continue the use of ACEIs and ARBs in COVID-19 patients with hypertension." @default.
• W3033156668 created "2020-06-12" @default.
• W3033156668 creator A5001549158 @default.
• W3033156668 creator A5029217927 @default.
• W3033156668 creator A5068186079 @default.
• W3033156668 date "2020-06-08" @default.
• W3033156668 modified "2023-10-18" @default.
• W3033156668 title "Association Between ACEIs or ARBs Use and Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-analysis" @default.
• W3033156668 cites W1784175517 @default.
• W3033156668 cites W1979423827 @default.
• W3033156668 cites W1987319584 @default.
• W3033156668 cites W2091671824 @default.
• W3033156668 cites W2092333633 @default.
• W3033156668 cites W2100224535 @default.
• W3033156668 cites W2157823046 @default.
• W3033156668 cites W2170892587 @default.
• W3033156668 cites W2436234996 @default.
• W3033156668 cites W2914853620 @default.
• W3033156668 cites W3004280078 @default.
• W3033156668 cites W3005655936 @default.
• W3033156668 cites W3009885589 @default.
• W3033156668 cites W3009941720 @default.
• W3033156668 cites W3010441732 @default.
• W3033156668 cites W3011254885 @default.
• W3033156668 cites W3012184818 @default.
• W3033156668 cites W3012285389 @default.
• W3033156668 cites W3012339747 @default.
• W3033156668 cites W3012747666 @default.
• W3033156668 cites W3012771079 @default.
• W3033156668 cites W3013231340 @default.
• W3033156668 cites W3013442544 @default.
• W3033156668 cites W3013564424 @default.
• W3033156668 cites W3013824443 @default.
• W3033156668 cites W3013871850 @default.
• W3033156668 cites W3013894115 @default.
• W3033156668 cites W3014571869 @default.
• W3033156668 cites W3014662258 @default.
• W3033156668 cites W3014797709 @default.
• W3033156668 cites W3014972079 @default.
• W3033156668 cites W3015407900 @default.
• W3033156668 cites W3015539298 @default.
• W3033156668 cites W3015590289 @default.
• W3033156668 cites W3015761555 @default.
• W3033156668 cites W3015824279 @default.
• W3033156668 cites W3016154560 @default.
• W3033156668 cites W3016283232 @default.
• W3033156668 cites W3016358278 @default.
• W3033156668 cites W3016535995 @default.
• W3033156668 cites W3016553045 @default.
• W3033156668 cites W3016572296 @default.
• W3033156668 cites W3016783119 @default.
• W3033156668 cites W3017238719 @default.
• W3033156668 cites W3017387364 @default.
• W3033156668 cites W3017545174 @default.
• W3033156668 cites W3017679265 @default.
• W3033156668 cites W3018494531 @default.
• W3033156668 cites W3019844653 @default.
• W3033156668 cites W3020049581 @default.
• W3033156668 cites W3020168167 @default.
• W3033156668 cites W3020646040 @default.
• W3033156668 cites W3021366174 @default.
• W3033156668 cites W3021992825 @default.
• W3033156668 cites W3022567999 @default.
• W3033156668 cites W3023640683 @default.
• W3033156668 cites W3023751598 @default.
• W3033156668 cites W3023826646 @default.
• W3033156668 cites W3024127574 @default.
• W3033156668 cites W3024432354 @default.
• W3033156668 cites W3024575398 @default.
• W3033156668 cites W3024919045 @default.
• W3033156668 cites W3025304547 @default.
• W3033156668 cites W3025732321 @default.
• W3033156668 cites W3026169961 @default.
• W3033156668 cites W3026300204 @default.
• W3033156668 cites W3026301311 @default.
• W3033156668 cites W3027217309 @default.
• W3033156668 cites W3027680906 @default.
• W3033156668 cites W3028492182 @default.
• W3033156668 cites W3028575869 @default.
• W3033156668 cites W3028972713 @default.
• W3033156668 cites W3030868216 @default.
• W3033156668 cites W3037521489 @default.
• W3033156668 cites W3040730385 @default.
• W3033156668 cites W3106147383 @default.
• W3033156668 cites W4206014212 @default.
• W3033156668 cites W4233006674 @default.
• W3033156668 cites W747235873 @default.
• W3033156668 doi "https://doi.org/10.1101/2020.06.03.20120261" @default.
• W3033156668 hasPublicationYear "2020" @default.
• W3033156668 type Work @default.
• W3033156668 sameAs 3033156668 @default.
• W3033156668 citedByCount "4" @default.
• W3033156668 countsByYear W30331566682020 @default.
• W3033156668 countsByYear W30331566682021 @default.
• W3033156668 countsByYear W30331566682022 @default.
• W3033156668 crossrefType "posted-content" @default.
• W3033156668 hasAuthorship W3033156668A5001549158 @default.
• W3033156668 hasAuthorship W3033156668A5029217927 @default.
• W3033156668 hasAuthorship W3033156668A5068186079 @default.
• W3033156668 hasBestOaLocation W30331566681 @default.

• next